There are currently 1329 clinical trials in Atlanta, Georgia looking for participants to engage in research studies. Trials are conducted at various facilities, including Emory University, Emory University Hospital, Emory University Hospital/Winship Cancer Institute and Children's Health Care of Atlanta. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
NCT05208307
Recruiting
This phase II trial studies the effect of belantamab mafodotin, pomalidomide, and dexamethasone in treating patents with high-risk myeloma. Belantamab mafodotin is a monoclonal antibody, called belantamab, linked to a chemotherapy drug, called mafodotin. Belantamab is a form of targeted therapy because it attaches to specific molecules on the surface of cancer cells, known as BCMA receptors, and delivers mafodotin to kill them. Chemotherapy drugs, such as pomalidomide, work in different ways to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2024
Locations: Emory University/Winship Cancer Institute, Atlanta, Georgia
Conditions: Plasma Cell Myeloma
Register for Updates
ABTECT - Maintenance
NCT05535946
Recruiting
This is a multicenter, randomized, placebo-controlled study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once daily (QD) as maintenance therapy in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies \[corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)\] and/or advanced therapies \[biologics (TNF inhi... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
08/06/2024
Locations: Digestive Healthcare of Georgia, Atlanta, Georgia
Conditions: Ulcerative Colitis
Register for Updates
Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer
NCT05998135
Recruiting
This phase II trial test tests how well repurposing atovaquone works in treating patients with platinum-resistant ovarian cancer. Atovaquone is used for the treatment or prevention of certain infections. Atovaquone is in a class of medications called antiprotozoal agents. It works by stopping the growth of certain types of protozoa that can cause pneumonia. Giving atovaquone may be effective in treating platinum-resistant ovarian cancer and result in improved outcomes compared to standard chemot... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/06/2024
Locations: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Conditions: Ovarian High Grade Serous Adenocarcinoma, Platinum-Resistant Ovarian Carcinoma
Register for Updates
PD, PK, and Safety of ALTO-203 in Patients With MDD
NCT06391593
Recruiting
The goal of this clinical trial is to determine the pharmacodynamic effects of ALTO-203 in patients with MDD in a randomized, placebo-controlled, single-dose crossover treatment period. Additionally, safety, tolerability, and PK will be assessed in a subsequent randomized placebo-controlled multi-dose parallel-group treatment period of 28 days. Participants will complete subjective response questionnaires and perform cognitive tasks during the single-dose period, in which participants will rece... Read More
Gender:
ALL
Ages:
Between 25 years and 64 years
Trial Updated:
08/05/2024
Locations: Site 4031, Atlanta, Georgia
Conditions: Major Depressive Disorder, Anhedonia
Register for Updates
Type 1 Diabetes Education and Support Study
NCT05735340
Recruiting
Diabetes distress has been identified as one of the largest contributors to the racial disparity in glycemic control that disproportionately burdens Black patients ages 18-30 years with type 1 diabetes (T1D). In order to combat this issue, this study assesses the feasibility of the culturally tailored intervention T1DES and evaluates the effect of the T1DES intervention on diabetes outcomes in a pilot randomized clinical trial among Black young adults with T1D.
Gender:
ALL
Ages:
Between 18 years and 30 years
Trial Updated:
08/02/2024
Locations: Kaiser Permanente Georgia, Atlanta, Georgia
Conditions: Type1diabetes
Register for Updates
Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors
NCT03611595
Recruiting
This study is being conducted in order to determine the safety, dose-limiting toxicities, and maximum tolerated dose of cabozantinib in combination with 13-cis-retinoic acid in patients with relapsed or refractory solid tumors including tumors of the central nervous system (CNS)
Gender:
ALL
Ages:
Between 2 years and 26 years
Trial Updated:
08/01/2024
Locations: Children's Healthcare of Atlanta, Atlanta, Georgia
Conditions: Solid Tumor
Register for Updates
Smoke Free SafeCare: Establishing a Smoke Free Home in CPS-involved Families
NCT05000632
Recruiting
Smoke Free SafeCare (SFSC) is a proposed braided intervention consisting of two evidence-based interventions: Some Things are Better Outside (STBO), aimed at promoting smoke free home rules, and SafeCare, aimed at reducing child maltreatment and improving mother and child outcomes. STBO is effective in creating smoke free homes and reducing second-hand smoke in low-SES (socioeconomic status) households. SafeCare is an effective parent training program that is broadly disseminated in child protec... Read More
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
08/01/2024
Locations: Georgia State University, Atlanta, Georgia
Conditions: Child Maltreatment, Smoking Behaviors
Register for Updates
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
NCT06271252
Recruiting
The is a first clinical study for Oricell Therapeutics Inc. in the United States to evaluate the safety, PK, PD and preliminary efficacy of our anti-GPRC5D cell product (OriCAR-017) in subjects with relapsed/refractory multiple myeloma. RIGEL Study
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/01/2024
Locations: Northside Hospital, Atlanta, Georgia
Conditions: Neoplasms, Plasma Cell, Neoplasms by Histologic Type, Neoplasms, Hemostatic Disorders, Vascular Diseases, Cardiovascular Diseases, Paraproteinemias, Blood Protein Disorders, Hematologic Diseases, Hemorrhagic Disorders, Lymphoproliferative Disorders, Immunoproliferative Disorders, Immune System Diseases, Multiple Myeloma
Register for Updates
Study to Determine the Pharmacokinetics and Pharmacodynamic Effects of Phenylephrine on BP Via IV
NCT02323399
Recruiting
The primary objective of this study is to evaluate the dose effect of Phenylephrine Hydrochloride Injection on the treatment of clinically relevant decreased blood pressure in the pediatric population, ≥12 to 16 year old patients undergoing general and neuraxial anesthesia. The secondary objectives are to describe changes in blood pressure and heart rate, time to onset and to maximal response, and the duration of response; to assess the safety of the product in this population; and to character... Read More
Gender:
ALL
Ages:
Between 12 years and 16 years
Trial Updated:
07/22/2024
Locations: Children's Healthcare of Atlanta at Egleston, Atlanta, Georgia
Conditions: Hypotension
Register for Updates
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
NCT04879043
Recruiting
This study will assess the safety, tolerability, pharmacokinetics (PK) and the therapeutic potential of HDP-101 in patients with plasma cell disorders including multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2024
Locations: Winship Cancer Institute of Emory University, Atlanta, Georgia
Conditions: Multiple Myeloma, Plasma Cell Disorder
Register for Updates
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
NCT04198766
Recruiting
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda®). KEYTRUDA is a registered trademark of Merck Sharp \& Dohme LLC, a subsidiary of Merck \& Co., Inc., Rahway, NJ, USA.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2024
Locations: Winship Cancer Institute - Emory University, Atlanta, Georgia
Conditions: Solid Tumor, Non-Small Cell Lung Cancer, Melanoma, Head and Neck Cancer, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma
Register for Updates
Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.
NCT05271292
Recruiting
This is a Phase 1b/2, single-arm, open-label, dose-escalation study including 2 stages: Phase 1b: Dose-Escalation Stage (Single-Dose and Consecutive-Dose Periods) Phase 2: recommended Phase 2 dose (RP2D) of chiauranib will be given to all patients enrolled in this phase once daily for 28-day cycles continuously with no interruption between cycles.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2024
Locations: Winship Cancer Institute of Emory University, Atlanta, Georgia
Conditions: Advanced Solid Malignant Tumor, Small Cell Lung Cancer
Register for Updates